| Clinical outcomes with abemaciclib after prior CDK4/6 inhibitor progression in breast cancer: a multicenter experience SA Wander, HS Han, ML Zangardi, A Niemierko, V Mariotti, LSL Kim, J Xi, ... Journal of the National Comprehensive Cancer Network 1 (aop), 1-8, 2021 | 61 | 2021 |
| Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model P Chen, JF O'Neal, ND Ebelt, MA Cantrell, S Mitra, A Nasrazadani, ... PloS one 5 (5), e10443, 2010 | 61 | 2010 |
| Precision medicine in hormone receptor-positive breast cancer A Nasrazadani, RA Thomas, S Oesterreich, AV Lee Frontiers in oncology 8, 144, 2018 | 49 | 2018 |
| Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management T Hyder, CC Marino, S Ahmad, A Nasrazadani, AM Brufsky Frontiers in Endocrinology 12, 713700, 2021 | 47 | 2021 |
| Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis Z Li, Y Wu, ME Yates, N Tasdemir, A Bahreini, J Chen, KM Levine, ... Cancer research 82 (7), 1321-1339, 2022 | 36 | 2022 |
| Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection A Brufsky, JLG Marti, A Nasrazadani, MT Lotze Journal of translational medicine 18, 1-6, 2020 | 36 | 2020 |
| c-Jun N-terminal kinase 2 regulates multiple receptor tyrosine kinase pathways in mouse mammary tumor growth and metastasis A Nasrazadani, CL Van Den Berg Genes & cancer 2 (1), 31-45, 2011 | 34 | 2011 |
| Approaching neoadjuvant therapy in the management of early-stage breast cancer T Hyder, S Bhattacharya, K Gade, A Nasrazadani, AM Brufsky Breast Cancer: Targets and Therapy, 199-211, 2021 | 25 | 2021 |
| Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer S Oesterreich, A Nasrazadani, J Zou, N Carleton, T Onger, MD Wright, ... JNCI: Journal of the National Cancer Institute 114 (11), 1511-1522, 2022 | 21 | 2022 |
| The evolving landscape of HER2-directed breast cancer therapy JLG Marti, T Hyder, A Nasrazadani, AM Brufsky Current treatment options in oncology 21, 1-17, 2020 | 18 | 2020 |
| Neratinib: The emergence of a new player in the management of HER2+ breast cancer brain metastasis A Nasrazadani, A Brufsky Future Oncology 16 (7), 247-254, 2020 | 16 | 2020 |
| Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women N Carleton, A Nasrazadani, K Gade, S Beriwal, PN Barry, AM Brufsky, ... The Lancet Healthy Longevity 3 (1), e54-e66, 2022 | 11 | 2022 |
| Statins and endocrine resistance in breast cancer T Hyder, JLG Marti, A Nasrazadani, AM Brufsky Cancer Drug Resistance 4 (2), 356, 2021 | 10 | 2021 |
| Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma A Nasrazadani, Y Li, Y Fang, O Shah, JM Atkinson, JS Lee, PF McAuliffe, ... British journal of cancer 128 (6), 1030-1039, 2023 | 8 | 2023 |
| Combination chemotherapy regimen in a patient with metastatic malignant pheochromocytoma and neurofibromatosis type 1 S Otoukesh, CJ Cooper, W Lou, M Mojtahedzadeh, A Nasrazadani, ... The American Journal of Case Reports 15, 123, 2014 | 7 | 2014 |
| A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression JO Brett, TD Dubash, GN Johnson, A Niemierko, V Mariotti, LSL Kim, J Xi, ... JCO Precision Oncology 7, e2200532, 2023 | 6 | 2023 |
| Breast cancer mortality as a function of age A Nasrazadani, JLG Marti, KE Kip, OC Marroquin, L Lemon, SD Shapiro, ... Aging (Albany NY) 14 (3), 1186, 2022 | 5 | 2022 |
| Twenty-year follow-up of a phase II trial of taxotere/carboplatin/herceptin in patients with metastatic HER2-positive breast cancer JL Gomez Marti, A Nasrazadani, Y Ding, D Normolle, AM Brufsky The Oncologist 28 (11), e1123-e1126, 2023 | 4 | 2023 |
| CDK4/6 inhibitors: taking the place of chemotherapy? A Nasrazadani, AM Brufsky The Lancet Oncology 20 (10), 1329-1330, 2019 | 4 | 2019 |
| Accuracy of Ki-67 with Recurrence Score and Recurrence Score–Pathology–Clinical Assessment in Early Stage Breast Cancer A Nasrazadani, A Dwivedi, S Otoukesh, J Arenas, O Padilla, A Alvarado, ... Annals of Hematology and Oncology 1, 1011, 2014 | 4 | 2014 |
